STAMPEDE Radiotherapy Details
The STAMPEDE trial did NOT include stereotactic body radiotherapy (SBRT); patients received conventional external beam radiotherapy (EBRT) to the prostate. 1
Form of Radiotherapy Used in STAMPEDE
The STAMPEDE cohort utilized standard-of-care conventional radiotherapy to the prostate, not SBRT. This is a critical distinction when interpreting the trial's results and applying them to clinical practice.
Key Technical Details:
- Target: Prostate gland (primary tumor site)
- Technique: Conventional fractionated external beam radiotherapy
- Patient Population: Men with newly diagnosed metastatic prostate cancer
- Stratification: Results were analyzed by metastatic burden (low vs. high)
Clinical Outcomes by Metastatic Burden:
Low metastatic burden patients (42% of cohort):
- Prostate RT improved overall survival (HR = 0.64,95% CI 0.52-0.79, p < 0.001) 1
- 156 deaths in SOC+RT vs. 202 in SOC alone
- This represents the standard of care for this population
High metastatic burden patients (58% of cohort):
- No survival benefit from prostate RT (HR = 1.11,95% CI 0.96-1.28, p = 0.164) 1
- 386 deaths in SOC+RT vs. 375 in SOC alone
Important Clinical Caveats:
The evidence provided about SBRT 2, 3, 2, 3 pertains to spinal metastases, not primary prostate treatment. SBRT for spinal metastases achieves approximately 90% local control at 1 year and 54% complete pain response, but this is an entirely different clinical scenario than the STAMPEDE trial's intervention.
Do not conflate STAMPEDE's conventional prostate radiotherapy with SBRT for metastatic sites. The STAMPEDE trial specifically evaluated whether adding conventional RT to the primary prostate tumor improves outcomes in metastatic disease, finding benefit only in low-burden disease without quality of life detriment 1.